JP2008526824A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526824A5 JP2008526824A5 JP2007549955A JP2007549955A JP2008526824A5 JP 2008526824 A5 JP2008526824 A5 JP 2008526824A5 JP 2007549955 A JP2007549955 A JP 2007549955A JP 2007549955 A JP2007549955 A JP 2007549955A JP 2008526824 A5 JP2008526824 A5 JP 2008526824A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- indol
- pyrimidin
- amine
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 52
- -1 CF 3 Inorganic materials 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 14
- 239000003085 diluting agent Substances 0.000 claims 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims 12
- 125000002723 alicyclic group Chemical group 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 230000003796 beauty Effects 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000005549 heteroarylene group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 3
- QNMZWFNNJMGJPU-UHFFFAOYSA-N 4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 QNMZWFNNJMGJPU-UHFFFAOYSA-N 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- MFJBGNAKQQZROG-UHFFFAOYSA-N 1-[3-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]indol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)C=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 MFJBGNAKQQZROG-UHFFFAOYSA-N 0.000 claims 1
- ORYJIEHLXNBUDO-UHFFFAOYSA-N 1-[4-[2-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 ORYJIEHLXNBUDO-UHFFFAOYSA-N 0.000 claims 1
- QTEDNMKQFCBAAX-UHFFFAOYSA-N 1-[4-[2-[[4-(1h-indol-3-yl)pyrimidin-2-yl]amino]-6-methylphenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=C(C)C=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 QTEDNMKQFCBAAX-UHFFFAOYSA-N 0.000 claims 1
- ALVHKDFSUMXMAM-UHFFFAOYSA-N 1-[4-[2-[[4-(1h-indol-3-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 ALVHKDFSUMXMAM-UHFFFAOYSA-N 0.000 claims 1
- OHSNNALNCJKABP-UHFFFAOYSA-N 1-[4-[2-[[4-(7-methoxy-1h-indol-3-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C=1NC=2C(OC)=CC=CC=2C=1C(N=1)=CC=NC=1NC1=CC=CC=C1N1CCN(C(C)=O)CC1 OHSNNALNCJKABP-UHFFFAOYSA-N 0.000 claims 1
- GEHZQYLPZVLSBQ-UHFFFAOYSA-N 1-n-[4-(1h-indol-3-yl)pyrimidin-2-yl]-4-n,4-n-dimethylbenzene-1,4-diamine Chemical compound C1=CC(N(C)C)=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 GEHZQYLPZVLSBQ-UHFFFAOYSA-N 0.000 claims 1
- XCCVIORCKHCUBO-UHFFFAOYSA-N 3-[6-(4-bromophenyl)-2-piperazin-1-ylpyrimidin-4-yl]-1h-indole Chemical compound C1=CC(Br)=CC=C1C1=CC(C=2C3=CC=CC=C3NC=2)=NC(N2CCNCC2)=N1 XCCVIORCKHCUBO-UHFFFAOYSA-N 0.000 claims 1
- BSYRLFVDLLFKHN-UHFFFAOYSA-N 3-[6-(4-bromophenyl)-2-pyrrolidin-1-ylpyrimidin-4-yl]-1h-indole Chemical compound C1=CC(Br)=CC=C1C1=CC(C=2C3=CC=CC=C3NC=2)=NC(N2CCCC2)=N1 BSYRLFVDLLFKHN-UHFFFAOYSA-N 0.000 claims 1
- GCNIRIHGOROKHE-UHFFFAOYSA-N 4-(1-methylindol-3-yl)-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound C12=CC=CC=C2N(C)C=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 GCNIRIHGOROKHE-UHFFFAOYSA-N 0.000 claims 1
- IGBOLHKYTYGQHA-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-(2-methyl-4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound C=1C=C(NC=2N=C(C=CN=2)C=2C3=CC=CC=C3NC=2)C(C)=CC=1N1CCOCC1 IGBOLHKYTYGQHA-UHFFFAOYSA-N 0.000 claims 1
- KAOVBKLGTDLFFF-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(C=CN=2)C=2C3=CC=CC=C3NC=2)=C1 KAOVBKLGTDLFFF-UHFFFAOYSA-N 0.000 claims 1
- NSGNJVMFDJRZTQ-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-(3-methoxy-4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound COC1=CC(NC=2N=C(C=CN=2)C=2C3=CC=CC=C3NC=2)=CC=C1N1CCOCC1 NSGNJVMFDJRZTQ-UHFFFAOYSA-N 0.000 claims 1
- IFZZRTFWXXWCAG-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-(3-methyl-4-thiomorpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound CC1=CC(NC=2N=C(C=CN=2)C=2C3=CC=CC=C3NC=2)=CC=C1N1CCSCC1 IFZZRTFWXXWCAG-UHFFFAOYSA-N 0.000 claims 1
- YREMHFSLEPPRKL-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-(3-nitrophenyl)pyrimidin-2-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2N=C(C=CN=2)C=2C3=CC=CC=C3NC=2)=C1 YREMHFSLEPPRKL-UHFFFAOYSA-N 0.000 claims 1
- UFJLSLOQYSZPMI-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 UFJLSLOQYSZPMI-UHFFFAOYSA-N 0.000 claims 1
- PXGRGKDEILVGHC-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-(4-piperazin-1-ylphenyl)pyrimidin-2-amine Chemical compound C1CNCCN1C(C=C1)=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 PXGRGKDEILVGHC-UHFFFAOYSA-N 0.000 claims 1
- OJHMIXITQDAWHE-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-(6-methoxypyridin-3-yl)pyrimidin-2-amine Chemical compound C1=NC(OC)=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 OJHMIXITQDAWHE-UHFFFAOYSA-N 0.000 claims 1
- LINLHBQPNYMQFJ-UHFFFAOYSA-N 4-(1h-indol-3-yl)-n-[2-(4-methylpiperazin-1-yl)phenyl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1C1=CC=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 LINLHBQPNYMQFJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000003989 Aurora kinases Human genes 0.000 claims 1
- 108090000433 Aurora kinases Proteins 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims 1
- 239000012346 acetyl chloride Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- JAZZHCIYTHOJIC-UHFFFAOYSA-N cyclopropyl-[3-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]indol-1-yl]methanone Chemical compound C1=C(C=2N=C(NC=3C=CC(=CC=3)N3CCOCC3)N=CC=2)C2=CC=CC=C2N1C(=O)C1CC1 JAZZHCIYTHOJIC-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- LUFWSVASWTXJRR-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound C1=CC=C2C(C=3C=CN=C(N=3)NC3=CC=C4OCOC4=C3)=CNC2=C1 LUFWSVASWTXJRR-UHFFFAOYSA-N 0.000 claims 1
- BOQFTUSRPOGVOO-UHFFFAOYSA-N n-(3,5-dimethoxyphenyl)-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C(C=CN=2)C=2C3=CC=CC=C3NC=2)=C1 BOQFTUSRPOGVOO-UHFFFAOYSA-N 0.000 claims 1
- XQOMWIBDIAWJPS-UHFFFAOYSA-N n-(4-fluorophenyl)-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound C1=CC(F)=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 XQOMWIBDIAWJPS-UHFFFAOYSA-N 0.000 claims 1
- UHXXXKOMOCSVKR-UHFFFAOYSA-N n-[2-(2,6-dimethylmorpholin-4-yl)phenyl]-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound C1C(C)OC(C)CN1C1=CC=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 UHXXXKOMOCSVKR-UHFFFAOYSA-N 0.000 claims 1
- ZPCJDYUHELRFHH-UHFFFAOYSA-N n-[2-(3,5-dimethylpiperidin-1-yl)phenyl]-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound C1C(C)CC(C)CN1C1=CC=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 ZPCJDYUHELRFHH-UHFFFAOYSA-N 0.000 claims 1
- UZQPYJFQWWIAML-UHFFFAOYSA-N n-[2-(4-benzylpiperazin-1-yl)phenyl]-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound C1CN(C=2C(=CC=CC=2)NC=2N=C(C=CN=2)C=2C3=CC=CC=C3NC=2)CCN1CC1=CC=CC=C1 UZQPYJFQWWIAML-UHFFFAOYSA-N 0.000 claims 1
- UHXXXKOMOCSVKR-CALCHBBNSA-N n-[2-[(2s,6r)-2,6-dimethylmorpholin-4-yl]phenyl]-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound C1[C@@H](C)O[C@@H](C)CN1C1=CC=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 UHXXXKOMOCSVKR-CALCHBBNSA-N 0.000 claims 1
- UHXXXKOMOCSVKR-IRXDYDNUSA-N n-[2-[(2s,6s)-2,6-dimethylmorpholin-4-yl]phenyl]-4-(1h-indol-3-yl)pyrimidin-2-amine Chemical compound C1[C@H](C)O[C@@H](C)CN1C1=CC=CC=C1NC1=NC=CC(C=2C3=CC=CC=C3NC=2)=N1 UHXXXKOMOCSVKR-IRXDYDNUSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
- 0 Cc1c(C(C*)=O)c(c(*)c(*)c(*)c2*)c2[n]1 Chemical compound Cc1c(C(C*)=O)c(c(*)c(*)c(*)c2*)c2[n]1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0500492.4A GB0500492D0 (en) | 2005-01-11 | 2005-01-11 | Compound |
| PCT/GB2006/000087 WO2006075152A1 (en) | 2005-01-11 | 2006-01-11 | 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526824A JP2008526824A (ja) | 2008-07-24 |
| JP2008526824A5 true JP2008526824A5 (https=) | 2009-02-19 |
Family
ID=34203901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007549955A Pending JP2008526824A (ja) | 2005-01-11 | 2006-01-11 | ４−（１ｈ−インドール−３−イル）−ピリミジン−２−イルアミン誘導体及び治療におけるこれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090318446A1 (https=) |
| EP (1) | EP1836194A1 (https=) |
| JP (1) | JP2008526824A (https=) |
| CN (1) | CN101111490A (https=) |
| AU (1) | AU2006205710A1 (https=) |
| BR (1) | BRPI0606313A2 (https=) |
| CA (1) | CA2592723A1 (https=) |
| GB (1) | GB0500492D0 (https=) |
| IL (1) | IL184313A0 (https=) |
| MX (1) | MX2007008373A (https=) |
| WO (1) | WO2006075152A1 (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CA2659582A1 (en) * | 2006-06-22 | 2007-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP2066319B1 (en) | 2006-09-08 | 2012-02-01 | F. Hoffmann-La Roche AG | Benzotriazole kinase modulators |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| EP2283009B1 (en) * | 2008-05-16 | 2012-08-29 | F. Hoffmann-La Roche AG | Inhibitors of jnk |
| CN101723936B (zh) * | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| KR20170015566A (ko) | 2008-11-10 | 2017-02-08 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| ES2663222T3 (es) | 2008-12-19 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina útiles como inhibidores de la quinasa ATR |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| MX336731B (es) | 2010-01-28 | 2016-01-28 | Harvard College | Composiciones y metodos para potenciar la actividad de proteasoma. |
| CA2794153C (en) | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
| CN102858764B (zh) * | 2010-04-27 | 2014-08-20 | 和记黄埔医药（上海）有限公司 | 嘧啶基吲哚化合物 |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用なピラジン |
| JP5856151B2 (ja) | 2010-05-12 | 2016-02-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体 |
| US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| CA2803802A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| CA2819373A1 (en) | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| EP2688886A1 (en) | 2011-03-22 | 2014-01-29 | Amgen Inc. | Azole compounds as pim inhibitors |
| JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物 |
| DK2707101T3 (da) | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | Proteostaseregulatorer |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN103702990B (zh) | 2011-07-27 | 2015-09-09 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
| KR101283895B1 (ko) * | 2011-08-04 | 2013-07-16 | 한국해양과학기술원 | 5-하이드록시인돌 화합물 또는 해면동물 스칼라리스폰지아 추출물을 유효성분으로 함유하는 암 질환의 예방 및 치료를 위한 조성물 |
| KR20140084112A (ko) | 2011-09-30 | 2014-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049859A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SG10201606774UA (en) | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| DK3077397T3 (da) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf |
| CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| CN104892585B (zh) * | 2014-03-06 | 2018-07-03 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| PL3152212T3 (pl) | 2014-06-05 | 2020-06-15 | Vertex Pharmaceuticals Inc. | Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法 |
| BR112018005833B1 (pt) * | 2015-09-25 | 2023-10-10 | Dizal (Jiangsu) Pharmaceutical Co., Limited | Composto, sal farmaceuticamente aceitável, composição farmacêutica e uso do composto |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| AU2017269335B2 (en) | 2016-05-26 | 2021-07-01 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| DK3514153T3 (da) * | 2017-01-26 | 2021-09-27 | Hanmi Pharm Ind Co Ltd | Pyrimidinforbindelse og farmaceutisk anvendelse deraf |
| CN107987054B (zh) * | 2017-11-28 | 2020-05-19 | 四川大学 | 一种cdk2抑制剂 |
| EP3740207A4 (en) * | 2018-01-16 | 2021-10-13 | Syros Pharmaceuticals, Inc. | CYCLINE-DEPENDENT KINASE 7 (CDK7) INHIBITORS |
| CA3088529A1 (en) * | 2018-01-16 | 2019-07-25 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE |
| WO2019154177A1 (zh) * | 2018-02-12 | 2019-08-15 | 恩瑞生物医药科技（上海）有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
| KR101954370B1 (ko) * | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| AU2019203034B1 (en) * | 2018-07-25 | 2019-09-26 | Hanmi Pharm. Co., Ltd. | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
| JPWO2020071550A1 (ja) * | 2018-10-04 | 2021-09-24 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
| JP2020070270A (ja) * | 2018-11-01 | 2020-05-07 | 御木本製薬株式会社 | フィブロネクチン遺伝子発現促進剤 |
| CN113677346A (zh) * | 2018-11-01 | 2021-11-19 | 希洛斯医药品股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
| WO2020171649A1 (ko) * | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| PH12021551985A1 (en) | 2019-02-22 | 2022-08-22 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
| CN113784962B (zh) | 2019-02-27 | 2025-04-25 | 加利福尼亚大学董事会 | 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环 |
| KR20210144844A (ko) | 2019-03-29 | 2021-11-30 | 아스트라제네카 아베 | 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙 |
| MX2021013531A (es) | 2019-05-05 | 2022-02-11 | Qilu Regor Therapeutics Inc | Inhibidores de cdk. |
| CA3138648A1 (en) * | 2019-05-22 | 2020-11-26 | Shanghai Hansoh Biomedical Co., Ltd. | Indole derivative-containing inhibitor, preparation method therefor and application thereof |
| EA202290154A1 (ru) | 2019-06-27 | 2022-03-29 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты |
| CN114269742B (zh) * | 2019-07-10 | 2024-07-16 | 常州千红生化制药股份有限公司 | 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物 |
| US12233064B1 (en) * | 2019-07-12 | 2025-02-25 | University Of South Florida | Antarctic tunicate Synoicum species-derived alkaloids and methods of treatment |
| WO2021066443A1 (ko) * | 2019-09-30 | 2021-04-08 | 한미약품 주식회사 | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| WO2021084541A1 (en) * | 2019-10-31 | 2021-05-06 | Sol-Gel Technologies Ltd. | Treatment of hair loss disorders with a topical egfr inhibitor |
| EP4241773A4 (en) * | 2020-11-05 | 2024-10-16 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEUKEMIA WITH FLT3 INHIBITOR |
| TW202333668A (zh) | 2021-12-15 | 2023-09-01 | 美商德利克斯醫療公司 | 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3751742T3 (de) * | 1986-01-13 | 2002-11-21 | American Cyanamid Co., Wayne | 4,5,6-Substituierte 2-Pyrimidinamine |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| TW440563B (en) * | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| US20040171630A1 (en) * | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
| GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
-
2005
- 2005-01-11 GB GBGB0500492.4A patent/GB0500492D0/en not_active Ceased
-
2006
- 2006-01-11 BR BRPI0606313-6A patent/BRPI0606313A2/pt not_active IP Right Cessation
- 2006-01-11 EP EP06701760A patent/EP1836194A1/en not_active Withdrawn
- 2006-01-11 MX MX2007008373A patent/MX2007008373A/es not_active Application Discontinuation
- 2006-01-11 CN CNA2006800037688A patent/CN101111490A/zh active Pending
- 2006-01-11 US US11/794,449 patent/US20090318446A1/en not_active Abandoned
- 2006-01-11 AU AU2006205710A patent/AU2006205710A1/en not_active Abandoned
- 2006-01-11 WO PCT/GB2006/000087 patent/WO2006075152A1/en not_active Ceased
- 2006-01-11 CA CA002592723A patent/CA2592723A1/en not_active Abandoned
- 2006-01-11 JP JP2007549955A patent/JP2008526824A/ja active Pending
-
2007
- 2007-07-01 IL IL184313A patent/IL184313A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526824A5 (https=) | ||
| JP2007500178A5 (https=) | ||
| JP2007509117A5 (https=) | ||
| CA2820618C (en) | Use of sulfonylbenzamide compounds in the treatment of systemic lupus erythematosus, lupus nephritis, or sjogren's syndrome | |
| US10342796B2 (en) | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | |
| JP2014139226A5 (https=) | ||
| JP2020506171A5 (https=) | ||
| JP2009526072A5 (https=) | ||
| JP2009541268A5 (https=) | ||
| US20180305349A1 (en) | 1, 3, 4-Thiadiazole Compounds and Their Use in Treating Cancer | |
| CA2545527A1 (en) | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | |
| JP2007520540A5 (https=) | ||
| RU2005117340A (ru) | Производные пиримидо {4,5-d}пиримидина, обладающие противораковой активностью | |
| JP2014511869A5 (https=) | ||
| JP2014503567A5 (https=) | ||
| JP2013523889A5 (https=) | ||
| JP2008519790A5 (https=) | ||
| JP2003525279A5 (https=) | ||
| JP2006524645A5 (https=) | ||
| JP2018529770A5 (https=) | ||
| JP2013531055A5 (https=) | ||
| JPWO2021170109A5 (https=) | ||
| JP4110347B2 (ja) | 抗ｈｉｖ剤 | |
| JP2021519786A5 (https=) | ||
| RU2018102449A (ru) | Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии |